Tenofovir Conference Data

Medical Advocates
Tenofovir Disoproxil Fumarate (Viread)

Conference Citations

14th CROI
8th Int Congress on Drug Therapy in HIV Infection
XVI International AIDS Conference
13th CROI

Archives

Conference Main Page

Main New/Newsworthy

Home Page

Last Update: August 01, 2011
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

XVI International AIDS Conference

Efficacy and safety of tenofovir DF (TDF), emtricitabine (FTC) and efavirenz (EFV) compared to fixed dose
zidovudine/lamivudine (CBV) and EFV through 96 weeks in antiretroviral treatment-naīve patients
J. Gallant, A. Pozniak, E. DeJesus, et al
Abstract
CD4 cells increase in patients receiving the combination of TDF/ddI-EC with or without a NNRTI
J. Scott, M. Mashburn, P. Wolfe, et al
Abstract

Tenofovir-based regimens for Non-Occupational Post-Exposure Prophylaxis (NPEP): improved tolerability
and adherence compared to AZT-based regimens
K. Mayer, M. Mimiaga, D. Cohen, et al
Abstract
Effect of lamivudine- and tenofovir- based HAART on hepatitis B plasma DNA (HBV DNA) in
HIV/HBV co-infected individuals
V. Montessori, S. Guillemi, S. Villar del Saz
Abstract
Characteristics and predictors of hepatic flares within a randomized study of HBV therapy in
antiretroviral (ARV) naīve HIV/HBV co-infected patients in Thailand
A. Avihingsanon, G.V. Matthews, S.R. Lewin, et al
Abstract

HIV prevention using tenofovir: community participation in the formative phase of a HIV prevention trial
in Cambodia
P. Pisith, J. Roberts, S. Sim, et al
Abstract
Tenofovir does not increase the incidence of chemotherapy related nephrotoxicity
R. Jones, E. Low, M. Nelson, et al
Abstract
Tenofovir-associated renal toxicity
C Davies, AM Hall, IG Williams, et al
Abstract

Facilitated selection of tenofovir resistance in HIV-1 subtype C
B. Brenner, M. Oliveira, D. Moisi, et al
Abstract
Reversal of end stage liver disease in patients with HIV/HBV-related cirrhosis treated
with tenofovir
G. Matthews, D. Cooper, G. Dore
Abstract
Tenofovir-associated nephrotoxicity: is dose-dependent ritonavir administration a co-factor?
Holmes A., Lucke J., Maghidman S., et al
Abstract
Mechanism of CD4+ t cell depletion in patients exposed to tenofovir plus didanosine
de Mendoza C., Benito J.M., Zahonero N , et al
Abstract

Creatine elevations in patients on fixed dose tenofovir/emtricitabine (Truvada) or tenofovir
Piontkowsky D., Doran B., Heintz J.
Abstract

Tenofovir plasma concentrations were predictive of virological success at month 6 in a cohort of
non-adherent Caribbean HIV-infected patients
Cabie A., Pierre-Franįois S., Visseaux B., et al
Abstract
An estimation of the impact of a treatment including tenofovir DF on lipid metabolism and
cardiovascular risk of patients with HIV infection
Le Pen C., Bouchez M., Trylesinski A., Monchecourt F.
Abstract
Reduction in renal function for Thai HIV-1 patients starting therapy with tenofovir based HAART
Avihingsanon A., Kerr S., Avihingsanon Y., et al
Abstract
Tenofovir-based regimens for Non-Occupational Post-Exposure Prophylaxis (NPEP): improved
tolerability and adherence compared to AZT-based regimens
Mayer K., Mimiaga M., Cohen D., et al
Abstract
No change in creatinine clearance after tenofovir in Thai patients
Gayet-Ageron A., Ananworanich J., Jupimai T., et al
Abstract

Reversal of end stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir
Matthews G., Cooper D., Dore G.
Abstract

Facilitated selection of tenofovir resistance in HIV-1 subtype C
Brenner B., Oliveira M., Moisi D., et al
Abstract

Why the K65R doesnt show up upon a failed tenofovir based regimen?
Machouf N., Thomas R., Trottier B., Nguyen V.K.
Abstract
Tenofovir does not increase the incidence of chemotherapy related nephrotoxicity
Jones R., Low E., Nelson M., et al
Abstract
Renal toxicity in HIV/Hepatitis C co-infected individuals exposed to tenofovir and/or Ribavarin
Jones R., Bower M., Mandalia S., et al
Abstract
Tenofovir (TDF)- versus non-TDF-containing ART: renal safety in daily practice
Jaegel-Guedes E., Wolf E., von Krosigk A., et al
Abstract
Can the addition of a non steroidal anti-inflammatory drug (NSAID) to a tenofovir-based regimen
precipitate acute renal failure in HIV positive patients?
Trottier B., Talbot A., Marcotte S.
Abstract
High rates of tenofovir-related renal dysfunction: associations with low CD4 nadir, diabetes, and
tipranavir/ritonavir
Crum-Cianflone N., Medina S., Brandt C., et al
Abstract
Durability of tenofovir disoproxil fumarate (TDF) and didanosine-ec (ddI-ec) as a backbone regimen
in HIV+ patients who have developed a 184 mutation and resistance to lamivudine or emtricitabine in
receiving once a day antiretroviral therapy
Jordan W.C.
Abstract
Evaluation of hypophosphatemia in tenofovir disoproxil fumarate (TDF)-exposed and TDF-unexposed
HIV outpatients receiving HAART
Buchacz K., Brooks J.T., Tong T. et al
Abstract
Randomized controlled trial of once daily Tenofovir, 3TC and Lopinavir/ritonavir versus remaining on
the same regimen in HIV-infected patients virologically suppressed on their first PI-containing HAART
regimen
Loutfy M., Ackad N., Baril J.-G. et al
Abstract
The effect of tenofovir+didanosine containing regimens on CD4 counts in treatment-experienced
patients at the Mildmay Centre, Uganda
Nabiddo L.K., Wilson B., Rukirande T.J.
Abstract

Antiretroviral resistance is not an important risk of the oral tenofovir prophylaxis trial in Botswana:
a simple mathematical modelling approach
Smith D., Kebaabetswe P., Disasi K., et al
Abstract

Overcoming the challenges of prevention research: lessons learned from the tenofovir pre-exposure
prophylaxis trials
Halima Y.
Abstract

13th Conference on Retroviruses and
Opportunistic Infections

A WEEK-IN-REVIEW FEATURED REPORT
POSTER
The Safety of Tenofovir DF for the Treatment of HIV Infection: The First 4 Years
M Nelson, D Cooper, R Schooley, et al
PDF Poster     Abstract

A 48-week Study of Tenofovir or Lamivudine or a Combination of Tenofovir and Lamivudine
for the Treatment of Chronic Hepatitis B in HIV/HBV-co-infected Individuals
M Nelson, S Bhagani, M Fisher, et al
"> Abstract

Effect of Tenofovir Disoproxil Fumarate-containing HAART on Bone Mineral Density in
HIV-infected Children
R Gafni, R Hazra, J Reynolds, et al
Abstract

K65R, L74V and Thymidine Analog Mutations in HIV-1 RT Associated with Reduced Response to
Tenofovir DF in ART-experienced Patients
J Waters, N Margot, D McColl, et al
Abstract

Rapid Emergence of Drug-resistant SIV in Tenofovir-treated Macaques: Implications for Tenofovir
Chemoprophylaxis against HIV
J Johnson, K Van Rompay, E Delwart, W Heneine
Abstract

POSTER
A Pharmacologic Basis for the Use of Tenofovir In Pre- and Post-exposure Prophylaxis: Intra-
and Extracellular Genital Tract Pharmacokinetics and Pharmacodynamics from First Dose to
Steady State in HIV-1-infected Men and Women
M Vourvahis, H Tappouni, K Patterson, et al
PDF Poster     Abstract

Prevention of Rectal SHIV Transmission in Macaques by Tenofovir/FTC Combination
J Garcia-Lerma, R Otten, S Qari, et al
Abstract

Differences in Calculated Glomerular Filtration Rates in Efavirenz- or Tenofovir-treated
Adults in ESS40006
M Thompson, R Haubrich D Margolis, et al
Abstract

Improvement in Lipoatrophy Associated with Highly Active Antiretroviral Therapy in
HIV-infected Children and Adolescents Switched from Stavudine to Tenofovir
A Viganō, P Brambilla, L Cafarelli. et al
Abstract

Didanosine and Lower Baseline Body Weight Are Associated with Declining Renal Function
among Patients Receiving Tenofovir
H Crane, R Harrington, S Van Rompaey, M Kitahata
Abstract

Randomized Intensification of a Triple Nucleoside Regimen with Efavirenz or Tenofovir in
ACTG 5095
R Gulick, C Lalama, C Shikum, et al
Abstract

Renal Impairment Associated with the Use of Tenofovir
J Heffelfinger, D Hanson, A Voetsch, et al
Abstract

Molecular Mechanism of Tenofovir, Abacavir, and Lamivudine Resistance by the K70E
Mutation in HIV-1 Reverse Transcriptase
Ni Sluis-Cremer, P Argoti Torres, J Grzybowski
Abstract

Tenofovir-induced Nephrotoxicity in the First Year of Therapy
J Guest, D Rimland, B Patterson, K Desilva
Abstract

Use Of Tenofovir Plus Didanosine Backbone In HIV-Infected Subjects Failing HAART
Bongiovanni M., Chiesa E., Cernat R, et al
Abstract

Conference Main Page Main New/Newsworthy Home Page

Tenofovir Conference Updates